Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRecruitment status now indicates no further participant recruitment; new help sections were added to assist users in reading, understanding, and joining studies, along with minor label formatting changes and a revision tag.SummaryDifference0.5%

- Check20 days agoChange DetectedThe page's revision tag was updated to v3.5.5, replacing v3.5.4. This represents a small internal update to the page's revision history and does not change the displayed study information.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page now displays a new revision label (v3.5.4), replacing the previous v3.5.3. This update reflects a new page revision in the metadata and does not change the underlying study content.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page’s displayed revision/version number was updated from v3.5.2 to v3.5.3. This reflects a tooling/version update without indicating changes to the study details.SummaryDifference0.1%

- Check70 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded 'B-cell chronic lymphocytic leukemia' as a disease keyword on the Study Details page.SummaryDifference0.1%

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.